DENVER--(BUSINESS WIRE)--Accelr8 Technology Corporation (Alternext: AXK) today announced that the company will collaborate with the Denver Health Medical Center (DHMC) in a study of ICU patients at risk for contracting ventilator-associated pneumonia (VAP). Denver Health is receiving funding for the study as a Team Science Award from the Colorado Clinical and Translational Sciences Institute (CCTSI, http://ctsa1.uchsc.edu). Accelr8 has provided analytical instrumentation to Denver Health for other studies, and in addition to the state funding will provide supplies needed to perform bacterial resistance analysis in this most recent study. Accelr8 will also provide related technical expertise.
